

# Kazuya Maeda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6785729/publications.pdf>

Version: 2024-02-01

142  
papers

8,189  
citations

43973

48  
h-index

49773

87  
g-index

152  
all docs

152  
docs citations

152  
times ranked

4153  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 139-146.   | 1.3 | 427       |
| 2  | Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 45-78.   | 1.1 | 345       |
| 3  | Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 328, 652-662.  | 1.3 | 333       |
| 4  | Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2014-2023.  | 1.7 | 322       |
| 5  | DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1229-1236.   | 1.7 | 280       |
| 6  | Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin. <i>Molecular Pharmacology</i> , 2005, 68, 800-807.  | 1.0 | 242       |
| 7  | Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 575-581.  | 2.3 | 192       |
| 8  | INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1247-1254.   | 1.7 | 190       |
| 9  | Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer Resistance Protein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1059-1067. | 1.3 | 189       |
| 10 | Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans. <i>Drug Metabolism and Disposition</i> , 2010, 38, 215-222.  | 1.7 | 182       |
| 11 | CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1477-1481.  | 1.7 | 176       |
| 12 | Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 427-439.   | 2.3 | 173       |
| 13 | Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 876-882.   | 1.3 | 167       |
| 14 | PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1109-1115.   | 1.7 | 164       |
| 15 | SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 541-547.   | 2.3 | 147       |
| 16 | Transporter-Mediated Drug-Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 1053-1064.   | 2.3 | 144       |
| 17 | Impact of Genetic Polymorphisms of Transporters on the Pharmacokinetic, Pharmacodynamic and Toxicological Properties of Anionic Drugs. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 223-235.   | 1.1 | 139       |
| 18 | Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2015, 43, 235-247.   | 1.7 | 125       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor. <i>Drug Metabolism and Disposition</i> , 2007, 35, 2166-2176.   | 1.7 | 122       |
| 20 | Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an <i>in vivo</i> inhibitor of BCRP. <i>British Journal of Pharmacology</i> , 2012, 166, 1793-1803.  | 2.7 | 118       |
| 21 | Organic Anion Transporting Polypeptide (OATP)1B1 and OATP1B3 as Important Regulators of the Pharmacokinetics of Substrate Drugs. <i>Biological and Pharmaceutical Bulletin</i> , 2015, 38, 155-168.  | 0.6 | 114       |
| 22 | Hepatic and Intestinal Drug Transporters: Prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 581-612.   | 4.2 | 111       |
| 23 | PET Imaging-Based Evaluation of Hepatobiliary Transport in Humans with $^{15}\text{O}$ -C-TIC-Me. <i>Journal of Nuclear Medicine</i> , 2012, 53, 741-748.  | 2.8 | 101       |
| 24 | The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine. <i>Drug Metabolism and Disposition</i> , 2009, 37, 555-559.   | 1.7 | 97        |
| 25 | Characterization of Organic Anion Transporting Polypeptide (OATP) Expression and Its Functional Contribution to the Uptake of Substrates in Human Hepatocytes. <i>Molecular Pharmaceutics</i> , 2012, 9, 3535-3542.  | 2.3 | 94        |
| 26 | Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1078-1089.  | 1.0 | 91        |
| 27 | Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1031-1038.                   | 1.7 | 87        |
| 28 | Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17 $\beta$ -Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1859-1866.         | 1.7 | 84        |
| 29 | Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine. <i>Molecular Pharmacology</i> , 2008, 73, 1474-1483.   | 1.0 | 83        |
| 30 | Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 513-523.   | 2.3 | 81        |
| 31 | Establishment of a Set of Double Transfectants Coexpressing Organic Anion Transporting Polypeptide 1B3 and Hepatic Efflux Transporters for the Characterization of the Hepatobiliary Transport of Telmisartan Acylglucuronide. <i>Drug Metabolism and Disposition</i> , 2008, 36, 796-805. | 1.7 | 78        |
| 32 | Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans. <i>Drug Metabolism and Disposition</i> , 2008, 36, 663-669.  | 1.7 | 78        |
| 33 | Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 59, 94-103.                              | 1.9 | 78        |
| 34 | Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 37-51.  | 2.3 | 76        |
| 35 | Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using In Vitro Uptake Experiments. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1471-1479.   | 1.7 | 72        |
| 36 | Culture Period-Dependent Changes in the Uptake of Transporter Substrates in Sandwich-Cultured Rat and Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1503-1510.   | 1.7 | 71        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers. <i>Pharmaceutical Research</i> , 2018, 35, 138.   | 1.7  | 69        |
| 38 | Uptake of Ursodeoxycholate and Its Conjugates by Human Hepatocytes: Role of Na <sup>+</sup> -Taurocholate Cotransporting Polypeptide (NTCP), Organic Anion Transporting Polypeptide (OATP) 1B1 (OATP-C), and OATP1B3 (OATP8). <i>Molecular Pharmaceutics</i> , 2006, 3, 70-77. | 2.3  | 68        |
| 39 | INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID. <i>Drug Metabolism and Disposition</i> , 2006, 34, 743-747.   | 1.7  | 68        |
| 40 | A microsensing system for the in vivo real-time detection of local drug kinetics. <i>Nature Biomedical Engineering</i> , 2017, 1, 654-666.   | 11.6 | 68        |
| 41 | Critical Role of Organic Anion Transporters 1 and 3 in Kidney Accumulation and Toxicity of Aristolochic Acid I. <i>Molecular Pharmaceutics</i> , 2011, 8, 2183-2192.   | 2.3  | 67        |
| 42 | Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers. <i>Pharmaceutical Research</i> , 2017, 34, 1601-1614.                     | 1.7  | 57        |
| 43 | Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1925-1933.  | 1.7  | 55        |
| 44 | The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 523-530.   | 0.7  | 54        |
| 45 | The Involvement of Organic Anion Transporting Polypeptide in the Hepatic Uptake of Telmisartan in Rats: PET Studies with [ <sup>11</sup> C]Telmisartan. <i>Molecular Pharmaceutics</i> , 2011, 8, 1789-1798.   | 2.3  | 52        |
| 46 | Transporter Database, TP-Search: A Web-Accessible Comprehensive Database for Research in Pharmacokinetics of Drugs. <i>Pharmaceutical Research</i> , 2004, 21, 2133-2134.  | 1.7  | 51        |
| 47 | Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion Using Newly Developed Positron Emission Tomography Tracer [ <sup>11</sup> C]Dehydropravastatin in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 193-202.                   | 1.3  | 51        |
| 48 | PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 739-747.   | 1.3  | 51        |
| 49 | Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 78-86.   | 1.1  | 51        |
| 50 | A Clinical Quantitative Evaluation of Hepatobiliary Transport of [ <sup>11</sup> C]Dehydropravastatin in Humans Using Positron Emission Tomography. <i>Drug Metabolism and Disposition</i> , 2018, 46, 719-728.  | 1.7  | 49        |
| 51 | The Eighth and Ninth Transmembrane Domains in Organic Anion Transporting Polypeptide 1B1 Affect the Transport Kinetics of Estrone-3-Sulfate and Estradiol-17 $\beta$ -D-glucuronide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 551-557.        | 1.3  | 48        |
| 52 | Novel strategies for microdose studies using non-radiolabeled compounds. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 532-538.  | 6.6  | 47        |
| 53 | <sup>125</sup> I-Hydrocortisol Is an Endogenous Probe for Evaluation of Drug-Drug Interactions Involving a Multispecific Renal Organic Anion Transporter, OAT3/SLC22A8, in Healthy Subjects. <i>Drug Metabolism and Disposition</i> , 2014, 42, 685-694.                       | 1.7  | 47        |
| 54 | Whole-body distribution and radiation dosimetry of [ <sup>11</sup> C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. <i>Nuclear Medicine and Biology</i> , 2012, 39, 847-853.  | 0.3  | 46        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Positron Emission Tomography Studies Using (15 <i>R</i> )-16- <i>m</i> -[ <sup>11</sup> C]tolyl-17,18,19,20-tetranorisocabacyclin Methyl Ester for the Evaluation of Hepatobiliary Transport. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 314-323. | 1.3 | 45        |
| 56 | Expression and Transport Function of Drug Uptake Transporters in Differentiated HepaRG Cells. <i>Molecular Pharmaceutics</i> , 2012, 9, 3434-3441.   | 2.3 | 45        |
| 57 | Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 263-270.   | 2.3 | 44        |
| 58 | Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 495-505.   | 0.7 | 44        |
| 59 | Investigation of Fluorescein Derivatives as Substrates of Organic Anion Transporting Polypeptide (OATP) 1B1 To Develop Sensitive Fluorescence-Based OATP1B1 Inhibition Assays. <i>Molecular Pharmaceutics</i> , 2016, 13, 438-448.   | 2.3 | 44        |
| 60 | Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different In Vitro In Vivo Extrapolation Approaches. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2678-2687.                            | 1.6 | 43        |
| 61 | Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2688-2694.                              | 1.6 | 43        |
| 62 | Estimation of the Three-Dimensional Pharmacophore of Ligands for Rat Multidrug-Resistance-Associated Protein 2 Using Ligand-Based Drug Design Techniques. <i>Pharmaceutical Research</i> , 2005, 22, 260-269.  | 1.7 | 42        |
| 63 | In Vivo Biliary Clearance Should Be Predicted by Intrinsic Biliary Clearance in Sandwich-Cultured Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2012, 40, 602-609.   | 1.7 | 41        |
| 64 | Transporter biology in drug approval: Regulatory aspects. <i>Molecular Aspects of Medicine</i> , 2013, 34, 711-718.  | 2.7 | 41        |
| 65 | Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1622-1632.   | 1.7 | 41        |
| 66 | Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins. <i>Drug Metabolism and Disposition</i> , 2017, 45, 779-789.  | 1.7 | 41        |
| 67 | Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data. <i>Pharmaceutical Research</i> , 2009, 26, 822-835.   | 1.7 | 37        |
| 68 | DNA Methylation Profiles of Organic Anion Transporting Polypeptide 1B3 in Cancer Cell Lines. <i>Pharmaceutical Research</i> , 2010, 27, 510-516.   | 1.7 | 36        |
| 69 | The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1808-1818.  | 1.7 | 36        |
| 70 | In Silico Classification of Major Clearance Pathways of Drugs with Their Physicochemical Parameters. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1362-1370.   | 1.7 | 35        |
| 71 | Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 377, 617-628.   | 1.4 | 34        |
| 72 | A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2017, 34, 1570-1583.   | 1.7 | 34        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes. <i>Molecular Pharmaceutics</i> , 2018, 15, 2277-2288.   | 2.3 | 32        |
| 74 | Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p-glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 654-661. | 1.0 | 30        |
| 75 | Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2542-2550.  | 1.6 | 30        |
| 76 | The Use of Hepatocytes to Investigate Drug Uptake Transporters. <i>Methods in Molecular Biology</i> , 2010, 640, 327-353.  | 0.4 | 30        |
| 77 | pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes. <i>Journal of Controlled Release</i> , 2002, 82, 71-82.   | 4.8 | 28        |
| 78 | Involvement of Different Human Glutathione Transferase Isoforms in the Glutathione Conjugation of Reactive Metabolites of Troglitazone. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2290-2297.  | 1.7 | 26        |
| 79 | Elucidation of <i>N</i> <sup>1</sup> -methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1270-1280.                                     | 1.7 | 25        |
| 80 | Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models. <i>BMC Systems Biology</i> , 2013, 7, S3.  | 3.0 | 24        |
| 81 | In Silico Prediction of Major Drug Clearance Pathways by Support Vector Machines with Feature-Selected Descriptors. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1811-1819.  | 1.7 | 24        |
| 82 | Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel. <i>Drug Metabolism and Disposition</i> , 2020, 48, 387-394.                          | 1.7 | 23        |
| 83 | Usability of Polydimethylsiloxane-Based Microfluidic Devices in Pharmaceutical Research Using Human Hepatocytes. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 3648-3657.   | 2.6 | 23        |
| 84 | Hepatic Uptake in the Dog: Comparison of Uptake in Hepatocytes and Human Embryonic Kidney Cells Expressing Dog Organic Anion-Transporting Polypeptide 1B4. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2361-2369.   | 1.7 | 22        |
| 85 | Involvement of Organic Cation Transporters in the Clearance and Milk Secretion of Thiamine in Mice. <i>Pharmaceutical Research</i> , 2015, 32, 2192-2204.  | 1.7 | 22        |
| 86 | Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects. <i>Drug Metabolism and Pharmacokinetics</i> , 2015, 30, 221-226.   | 1.1 | 21        |
| 87 | Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum. <i>Drug Metabolism and Disposition</i> , 2021, 49, 84-93.   | 1.7 | 21        |
| 88 | Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information on <i>SLCO1B1</i> and <i>ABCC2</i> Polymorphisms. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1309-1317.  | 1.0 | 20        |
| 89 | Possible Role of Organic Cation Transporters in the Distribution of [ <sup>11</sup> C]Sulpiride, a Dopamine D <sub>2</sub> Receptor Antagonist. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2558-2565.  | 1.6 | 20        |
| 90 | Clinical Relevance of Liquid Chromatography Tandem Mass Spectrometry as an Analytical Method in Microdose Clinical Studies. <i>Pharmaceutical Research</i> , 2011, 28, 1963-1972.  | 1.7 | 19        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | The synthesis of [ <sup>18</sup> F]pitavastatin as a tracer for hOATP using the Suzuki coupling. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 1113-1121.   | 1.5 | 19        |
| 92  | Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 37, 100358.   | 1.1 | 19        |
| 93  | Cost-effectiveness Analysis of Microdose Clinical Trials in Drug Development. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 187-195.  | 1.1 | 18        |
| 94  | Quantitative Analysis of the ABCG2 c.421C > A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3039-3048.  | 1.6 | 18        |
| 95  | Generation of Human-Induced Pluripotent Stem Cell-Derived Functional Enterocyte-Like Cells for Pharmacokinetic Studies. <i>Stem Cell Reports</i> , 2021, 16, 295-308.   | 2.3 | 18        |
| 96  | Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 689-700.  | 0.3 | 18        |
| 97  | Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 125, 181-192. | 1.9 | 17        |
| 98  | Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1315-1323.  | 2.3 | 16        |
| 99  | Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 344-354.   | 0.7 | 15        |
| 100 | Investigation of the Effect of the Uneven Distribution of CYP3A4 and P-Glycoprotein in the Intestine on the Barrier Function against Xenobiotics: A Simulation Study. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3196-3204.   | 1.6 | 14        |
| 101 | Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2739-2750.               | 1.6 | 14        |
| 102 | Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2222-2230.   | 1.6 | 13        |
| 103 | Quantitative investigation of hepatobiliary transport of [ <sup>11</sup> C]telmisartan in humans by PET imaging. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 293-299.   | 1.1 | 13        |
| 104 | Physiologically based pharmacokinetic model based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs. <i>Clinical and Translational Science</i> , 2022, 15, 1519-1531.  | 1.5 | 13        |
| 105 | Microdose pharmacogenetic study of <sup>14</sup> C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9*3 on its pharmacokinetics and metabolism. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 642-648.  | 1.9 | 12        |
| 106 | A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 793-801.  | 1.1 | 12        |
| 107 | Classification of drugs for evaluating drug interaction in drug development and clinical management. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 41, 100414.  | 1.1 | 12        |
| 108 | Studies on the Intestinal Absorption Characteristics of Sulfasalazine a Breast Cancer Resistance Protein (BCRP) Substrate. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 71-74.   | 1.1 | 11        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Usefulness of A Model-Based Approach for Estimating In Vitro P-Glycoprotein Inhibition Potency in a Transcellular Transport Assay. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 891-896.  | 1.6 | 11        |
| 110 | Organic Anion Transporting Polypeptide 1a4 is Responsible for the Hepatic Uptake of Cardiac Glycosides in Mice. <i>Drug Metabolism and Disposition</i> , 2018, 46, 652-657.   | 1.7 | 11        |
| 111 | Usefulness of Human Jejunal Spheroid-Derived Differentiated Intestinal Epithelial Cells for the Prediction of Intestinal Drug Absorption in Humans. <i>Drug Metabolism and Disposition</i> , 2022, 50, 204-213.   | 1.7 | 11        |
| 112 | Is Ethnic Variability in the Exposure to Rosuvastatin Explained Only by Genetic Polymorphisms in OATP1B1 and BCRP or Should the Contribution of Intrinsic Ethnic Differences in OATP1B1 Be Considered?. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2227-2230.   | 1.6 | 10        |
| 113 | In Silico Prediction of Major Clearance Pathways of Drugs among 9 Routes with Two-Step Support Vector Machines. <i>Pharmaceutical Research</i> , 2018, 35, 197.   | 1.7 | 10        |
| 114 | In Vitro-In Vivo Scale-up of Drug Transport Activities. , 0, , 557-588.   |     | 9         |
| 115 | Explication of Definitional Description and Empirical Use of Fraction of Orally Administered Drugs Absorbed From the Intestine (F <sub>a</sub> ) and Intestinal Availability (F <sub>g</sub> ): Effect of P-glycoprotein and CYP3A on F <sub>a</sub> and F <sub>g</sub> . <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 431-442. | 1.6 | 9         |
| 116 | The role of breast cancer resistance protein (Bcrp/Abcg2) in triptolide-induced testis toxicity. <i>Toxicology Research</i> , 2015, 4, 1260-1268.   | 0.9 | 8         |
| 117 | Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 387-395.   | 1.1 | 8         |
| 118 | Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 87-94.   | 1.1 | 8         |
| 119 | Evaluation of Hepatic Uptake of OATP1B Substrates by Short Term-Cultured Plated Human Hepatocytes: Comparison With Isolated Suspended Hepatocytes. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 376-387.  | 1.6 | 8         |
| 120 | <sup>64</sup> Cu-labeling of small extracellular vesicle surfaces via a cross-bridged macrocyclic chelator for pharmacokinetic study by positron emission tomography imaging. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121968.  | 2.6 | 8         |
| 121 | Determination of the Kinetic Parameters for <sup>123</sup> I Uptake by the Thyroid, Thyroid Weights, and Thyroid Volumes in Present-day Healthy Japanese Volunteers. <i>Health Physics</i> , 2020, 118, 417-426.  | 0.3 | 7         |
| 122 | Quantitative prediction of pharmacokinetic properties of drugs in humans: Recent advance in in vitro models to predict the impact of efflux transporters in the small intestine and blood-brain barrier. <i>Journal of Pharmacological Sciences</i> , 2022, 148, 142-151.   | 1.1 | 7         |
| 123 | Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug-Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1805-1816.       | 1.7 | 6         |
| 124 | Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug-drug interactions. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 76-88.  | 1.1 | 6         |
| 125 | Naphthalene-hydrophobized $\beta$ -1,3-glucan nanogel for doxorubicin delivery to immunocytes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1880-1883.   | 1.0 | 5         |
| 126 | Radiosynthesis of novel pitavastatin derivative ( <sup>18</sup> F]PTV-F1) as a tracer for hepatic OATP using a one-pot synthetic procedure. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 565-575.  | 0.5 | 5         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs. AAPS Journal, 2020, 22, 133. | 2.2 | 4         |
| 128 | Prediction of Hepatic Transporter-Mediated Drug-Drug Interaction from In Vitro Data. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 121-153.   | 0.2 | 3         |
| 129 | Clinical evaluation of [ <sup>18</sup> F]pitavastatin for quantitative analysis of hepatobiliary transporter activity. Drug Metabolism and Pharmacokinetics, 2022, 44, 100449.   | 1.1 | 3         |
| 130 | Direct and Rapid Genotyping of SLCO1B1 388A>G and 521T>C in Human Blood Specimens Using the SmartAmp-2 Method. AAPS Journal, 2013, 15, 618-622.  | 2.2 | 2         |
| 131 | Automated Extraction of Information on Chemical-P-glycoprotein Interactions from the Literature. Journal of Chemical Information and Modeling, 2013, 53, 2506-2510.  | 2.5 | 2         |
| 132 | Evaluation of transporter-mediated hepatobiliary transport of newly developed <sup>18</sup> F-labeled pitavastatin derivative, PTV-F1, in rats by PET imaging. Drug Metabolism and Pharmacokinetics, 2019, 34, 317-324.        | 1.1 | 2         |
| 133 | Web-Based Database as a Tool to Examine Drug-Drug Interactions Involving Transporters. , 2010, , 387-412.  |     | 2         |
| 134 | Determination of kinetic parameters for <sup>123</sup> I thyroid uptake in healthy Japanese. EPJ Web of Conferences, 2017, 153, 08007.   | 0.1 | 1         |
| 135 | Practical Synthesis of [ <sup>18</sup> F]Pitavastatin and Evaluation of Hepatobiliary Transport Activity in Rats by Positron Emission Tomography. Molecular Pharmaceutics, 2020, 17, 1884-1898.                                | 2.3 | 1         |
| 136 | Chapter 22. Impact of Drug Transporters in the Pharmacological and Adverse Reactions of Drugs. RSC Drug Discovery Series, 2011, , 563-598.   | 0.2 | 1         |
| 137 | 5. Microdose Clinical Study for Drug Development. Japanese Journal of Clinical Pharmacology and Therapeutics, 2009, 41, 27-34.   | 0.1 | 1         |
| 138 | Integrative analysis of transporter-mediated drug-drug interactions. Drug Delivery System, 2014, 29, 426-438.  | 0.0 | 0         |
| 139 | Prediction of drug interactions at transporters. Drug Metabolism and Pharmacokinetics, 2017, 32, S4.   | 1.1 | 0         |
| 140 | Prospect of in vitro Bile Fluids Collection in Improving Cell-Based Assay of Liver Function. Frontiers in Toxicology, 2021, 3, 657432.   | 1.6 | 0         |
| 141 | ŕ¼“ŕ¼Žăf~ăf ©ăf³ă,1ăfăf1/4ă,žăf1/4ă®é²ă1/4ăšăž<ăĒè—ŕç% ©ă•æ...ăf»è—ŕăš1ă*ă,žă•ă,ă,ăf³ăf‘ă,~ăf^ă€ŕ1/2žOATP1B1ŕ¼ŕ¼CEBCRP   |     |           |
| 142 | S13-1. Clinical Examples of Transporter-Mediated Drug-Drug Interactions and Their Evaluation Methods. Japanese Journal of Clinical Pharmacology and Therapeutics, 2012, 43, 253-254.   | 0.1 | 0         |